Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlycoMimetics has initiated a Phase I clinical trial for GMI-1070, its lead drug candidate for the treatment of vaso-occlusive crisis of sickle cell disease.
Subscribe to our email newsletter
The Phase I trial will evaluate the safety and pharmacokinetics of a single intravenous dose of GMI-1070 at a range of dose levels. The initial Phase I trial will be followed by additional multiple dose studies in healthy volunteers and, later, in sickle cell patients to further assess safety and to evaluate clinical effects.
According to the company, GMI-1070 is a rationally designed glycomimetic inhibitor of E-, P- and L-selectins, and inhibits a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed tissue.
Rachel King, CEO of GlycoMimetics, said: “We are pleased to advance our lead drug candidate into clinical trials. GMI-1070 possesses excellent drug-like properties and has demonstrated potency in preclinical studies of vaso-occlusive crisis as well as in other disease indications.”